Mucoactive drugs and multiple applications in pulmonary disease therapy

Area of Science:

• Pulmonary Medicine
• Biomaterials Science
• Pharmacology

Background:

• Mucus acts as a vital defense barrier in organs, including the lungs, protecting against pathogens and maintaining homeostasis.
• Hypersecretion of airway mucus is a hallmark of respiratory diseases such as Chronic Obstructive Pulmonary Disease (COPD) and Cystic Fibrosis (CF).
• Excessive mucus obstructs airways, diminishing lung function and the efficacy of inhaled medications.

Purpose of the Study:

• To review the classification and mechanisms of action of mucoactive drugs.
• To focus on the clinical application of mucoactive drugs in managing COPD and CF.
• To assess therapeutic strategies for mitigating airway obstruction caused by mucus.

Main Methods:

• Literature review of scientific articles and clinical studies on mucoactive drugs.
• Classification of mucoactive agents based on their therapeutic targets (expectorants, mucolytics, mucokinetics, mucoregulators).
• Analysis of clinical trial data for mucoactive therapies in COPD and CF patients.

Main Results:

• Mucoactive drugs offer diverse mechanisms to address mucus dysfunction in respiratory diseases.
• Clinical studies demonstrate varying efficacy of different mucoactive agents in improving mucus clearance and lung function in COPD and CF.
• Optimizing mucoactive drug selection and application is crucial for effective airway management.

Conclusions:

• Mucoactive drugs are essential in managing mucus-related respiratory conditions.
• Further research and clinical trials are needed to refine therapeutic strategies for COPD and CF using mucoactive agents.
• Targeting mucus properties offers a promising avenue for restoring pulmonary function in obstructive lung diseases.